Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Rhonda Voskuhl Stories

2012-01-19 05:30:00

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the initiation of the Phase II clinical trial of Trimesta(TM)( )(oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis (MS). This clinical trial is intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients at University...

2011-11-14 08:00:00

ANN ARBOR, Mich., Nov. 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its third quarter 2011 financial results for the period ended September 30, 2011, as well as updates since the beginning of the third quarter. Updates since the beginning of the third quarter include: Drug Development Programs Relapsing-Remitting Multiple Sclerosis (MS) As of September 19, 2011, the...

2011-11-11 08:00:00

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta(TM) (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this...

2011-09-19 07:57:00

ANN ARBOR, Mich., Sept. 19, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta(TM) (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol. The Company also announced that Rhonda Voskuhl,...

2011-05-03 08:00:00

ANN ARBOR, Mich., May 3, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that after scientific review, the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate for multiple sclerosis (MS) has received an additional $1,594,553 in grant funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS). The clinical...

2008-09-19 09:00:40

Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of autoimmune and central nervous system diseases, announced today that its scientific collaborator has presented new findings from a phase IIa clinical trial results using estriol for the treatment of multiple sclerosis at the World Congress on Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS, ECTRIMS and LACTRIMS) in Montreal, Canada....